ArticleOpen veterinary journal2026
Hypofractionated reirradiation for feline nasal epithelial tumors: A retrospective study.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Feline nasal epithelial tumors are locally invasive and radiosensitive, and radiotherapy is the standard treatment. However, recurrence is common, and the role of reirradiation in cats remains unclear. Aim: This retrospective study aimed to evaluate the efficacy and safety of hypofractionated reirradiation in cats with recurrent nasal epithelial tumors. Methods: The medical records of cats treated with hypofractionated radiotherapy for intranasal epithelial tumors at Azabu University Veterinary Teaching Hospital between 2014 and 2022 were reviewed. Follow-up continued until August 2023. Results: Twenty-six cats were treated, 11 of which underwent reirradiation after clinical progression. The median interval between treatments was 356 days. In the first course, responses included complete ( Conclusion: Hypofractionated reirradiation may be a viable salvage option for feline nasal epithelial tumors, particularly in cases with adenocarcinoma or early-stage disease, with acceptable toxicity when patients are carefully selected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.